FIELD: biotechnology.
SUBSTANCE: invention relates to a non-natural modified domain α 1-α 2 molecules of natural ligand NKG2D. Specified modified domainα 1-α 2 binds the non-natural NKG2D receptor and contains an amino acid sequence having at least 90% identity with the following SEQ ID NO: 4, wherein in the said amino acid sequence having at least 90% identity with the following SEQ ID NO: 4, positions corresponding to positions 8, 80, 154, 155, 156, 157, 158 and 159 of the following SEQ ID NO: 4, superseded from the following SEQ ID NO: 4). The invention provides high binding activity to the non-natural ectodomain of the NKG2D receptor containing the following amino acid sequence SEQ ID NO: 17 with substitutions Y75A and Y122F compared with (a) a non-natural NKG2D receptor ectodomain containing the following amino acid sequence SEQ ID NO: 17 having Y75A, and (b) the corresponding natural NKG2D receptor ectodomain containing the amino acid sequence SEQ ID NO: 17.
EFFECT: obtaining modified α1-α2 domains of non-natural nkg2d ligands that bind to non-natural nkg2d receptors.
11 cl, 18 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
Authors
Dates
2024-03-13—Published
2019-03-27—Filed